Related Experiment Videos
Transient neutropenia induced by clozapine
Psychopharmacology Bulletin
|January 1, 1992
Summary
Clozapine, an atypical antipsychotic, can cause blood dyscrasias like neutropenia. This study found a 22% cumulative incidence of transient neutropenia in first-time clozapine users, highlighting the need for careful monitoring.
Area of Science:
- Pharmacology
- Hematology
- Psychiatry
Background:
- Atypical antipsychotic clozapine is associated with blood dyscrasias, including potentially lethal agranulocytosis.
- Neutropenia, a decrease in neutrophil granulocytes, is a clinically significant side effect of clozapine and can indicate impending agranulocytosis.
Purpose of the Study:
- To analyze the incidence of neutropenia in patients initiating clozapine therapy.
- To assess the clinical relevance of transient neutropenia during clozapine treatment.
Main Methods:
- Analysis of data from a clozapine drug monitoring program.
- Inclusion of 68 patients receiving clozapine for the first time.
- Monitoring of neutrophil granulocyte counts.
Main Results:
- Two patients experienced severe neutropenia (290 and 660/mm3), with recovery after clozapine discontinuation.
- Eight additional patients showed transient neutropenia during ongoing clozapine administration.
- The cumulative incidence of transient neutropenia was 22% (95% CI 7.5%-36.5%).
Conclusions:
- Transient neutropenia is a relatively common side effect of clozapine therapy.
- Close hematologic monitoring is crucial for patients on clozapine to detect early signs of neutropenia and prevent severe complications.